Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Brief summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

RECRUITING

phase

PHASE2, PHASE3

study type

INTERVENTIONAL

enrollment

1541

sponsor

Celgene

conditions

Neoplasms

interventions

GENETIC: Gene-modified (GM) T cell therapy

start date

2018-07-19

start date type

ACTUAL

primary completion date

2043-05-29

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters